FAYE M JOHNSON to Neoplasms
This is a "connection" page, showing publications FAYE M JOHNSON has written about Neoplasms.
Connection Strength
0.365
-
End-of-life and goals of care discussions with cancer patients in the coronavirus pandemic. Palliat Support Care. 2021 06; 19(3):384-385.
Score: 0.120
-
Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer. 2010 Mar 15; 116(6):1582-91.
Score: 0.055
-
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem. 2007 Nov; 7(6):651-9.
Score: 0.047
-
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):67-73.
Score: 0.025
-
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol. 2018 08; 82(2):285-298.
Score: 0.024
-
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.
Score: 0.023
-
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. Mol Cancer Ther. 2016 10; 15(10):2334-2343.
Score: 0.021
-
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71.
Score: 0.021
-
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res. 2015 Feb 15; 21(4):693-700.
Score: 0.019
-
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
Score: 0.008